Regen BioPharma (RGBP) 10-Q 22 Jul 22 2022 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Jun. 30, 2022	Jul. 17, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2022
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--09-30
Entity File Number	333-191725
Entity Registrant Name	REGEN BIOPHARMA, INC.
Entity Central Index Key	0001589150
Entity Tax Identification Number	45-5192997
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	4700 Spring Street
Entity Address, Address Line Two	St 304
Entity Address, City or Town	La Mesa
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	91942
City Area Code	619
Local Phone Number	722-5505
Entity Current Reporting Status	No
Entity Interactive Data Current	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		4,970,002,832

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)	Jun. 30, 2022	Sep. 30, 2021
CURRENT ASSETS
Cash	$ 110,993	$ 727,162
Accounts Receivable, Related Party	295,466	213,192
Note Receivable, Related Party	5,396	5,396
Accrued Interest Receivable	629	230
Prepaid Expenses	27,801	48,144
Total Current Assets	440,286	994,124
OTHER ASSETS
Investment Securities	26,828	198,006
Investment Securities, Related Party	222,580	19,969
Total Other Assets	249,408	217,975
TOTAL ASSETS	689,693	1,212,099
Current Liabilities:
Accounts payable	28,799	91,498
Notes Payable	227	1,429,179
Accrued payroll taxes	4,241	4,241
Accrued Interest	691,985	954,861
Accrued Rent		0
Accrued Payroll	1,266,679	1,266,679
Other Accrued Expenses	41,423	41,423
Bank Overdraft	1,000	1,000
Due to Investor	20,000	20,000
Unearned Income	1,749,930	1,843,806
Derivative Liability	3,654,003	6,892,477
Convertible Notes Payable Less  unamortized discount	1,571,090	2,131,311
Convertible Notes Payable, Related Parties Less  unamortized discount	10,000	21,500
Total Current Liabilities	9,039,377	14,697,976
Long Term Liabilities:
Convertible Notes Payable, Related Parties Less  unamortized discount		0
Total Liabilities	9,039,377	14,697,976
STOCKHOLDERS' EQUITY (DEFICIT)
Common Stock ($.0001 par value) 500,000,000 shares authorized; 5,800,000,000 authorized and 4,920,002,832 issued and outstanding as of June 30,2022 and 4,800,000,000 authorized and 4,350,554,514 shares issued and outstanding as of September 30 ,2021.	491,999	435,054
Additional Paid in capital	11,200,998	8,644,037
Contributed Capital	736,326	736,326
Retained Earnings (Deficit)	(20,827,342)	(23,348,900)
Total Stockholders' Equity (Deficit)	(8,349,684)	(13,485,877)
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)	689,693	1,212,099
Series A Preferred Stock [Member]
STOCKHOLDERS' EQUITY (DEFICIT)
Preferred Stock, Value, Issued	43,929	43,200
Series A A Preferred Stock [Member]
STOCKHOLDERS' EQUITY (DEFICIT)
Preferred Stock, Value, Issued	5	5
Series M [Member]
STOCKHOLDERS' EQUITY (DEFICIT)
Preferred Stock, Value, Issued	4,400	4,400
Series N C [Member]
STOCKHOLDERS' EQUITY (DEFICIT)
Preferred Stock, Value, Issued	$ 1	$ 1

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2022	Sep. 30, 2021
Common Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Common Stock, Shares Authorized	5,800,000,000	4,800,000,000
Common Stock, Shares, Outstanding	4,920,002,832	4,350,554,514
Preferred Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Preferred Stock, Shares Authorized	800,000,000	800,000,000
Series A Preferred Stock [Member]
Preferred Stock, Shares Authorized	540,000,000	300,000,000
Preferred Stock, Shares Outstanding	439,293,406	431,998,817
Series A A Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share		$ 0.0001
Preferred Stock, Shares Authorized	600,000	600,000
Preferred Stock, Shares Outstanding	50,000	50,000
Series M [Member]
Preferred Stock, Par or Stated Value Per Share		$ 0.0001
Preferred Stock, Shares Authorized	60,000,000	300,000,000
Preferred Stock, Shares Outstanding	44,000,000	44,000,000
Series N C [Member]
Preferred Stock, Par or Stated Value Per Share		$ 0.0001
Preferred Stock, Shares Authorized	20,000	20,000
Preferred Stock, Shares Outstanding	10	10

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
REVENUES
Revenues	$ 31,292	$ 29,206	$ 93,877	$ 29,206
Revenues, Related Party	27,425	27,425	82,274	82,274
TOTAL REVENUES	58,717	56,631	176,151	111,480
COST AND EXPENSES
Research and Development	31,061	14,254	93,869	15,893
Research and Development, Related Party	0	0	117,250	0
General and Administrative	6,866	24,157	18,879	108,821
Consulting and Professional Fees	64,700	50,711	152,979	50,711
Rent	15,000	10,000	35,000	10,000
Total Costs and Expenses	117,627	99,122	417,977	185,425
OPERATING INCOME (LOSS)	(58,910)	(42,491)	(241,827)	(73,945)
OTHER INCOME & (EXPENSES)
Interest Income	133	96	399	96
Interest Expense	(30,399)	(59,569)	(107,970)	(198,029)
Interest Expense attributable to Amortrization of Discount	(22,203)	(414)	(66,631)	(47,063)
Penalties	0	0	(300,000)	0
Unrealized Gain ( Loss) on sale of Investment Securities	161,729	(308,550)	31,433	(308,550)
Gain(Loss) on sale of Investment Securities		(206,900)		(206,900)
Gain (Loss) on derecognition of Accounts Payable	0	0	62,700	0
Derivative Income (Expense)	66,907,817	(6,871,286)	3,238,473	(4,546,175)
Gain (Loss) on  Extinguishment Convertible Debt	0	0	(95,019)	0
TOTAL OTHER INCOME (EXPENSE)	67,017,077	(7,446,623)	2,763,384	(5,306,621)
NET INCOME (LOSS)	66,958,166	(7,489,114)	2,521,557	(5,380,566)
NET INCOME (LOSS) attributable to common shareholders	$ 60,931,932	$ (7,489,115)	$ 2,294,618	$ (5,380,566)
BASIC AND FULLY DILUTED EARNINGS (LOSS) PER SHARE	$ 0.01274	$ (0.0021)	$ 0.0005	$ (0.002)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING	4,783,780,610	3,573,338,986	4,794,127,177	2,608,298,343

Condensed Consolidated Statemen

Condensed Consolidated Statement of Shareholder's Deficit (Unaudited) - USD ($)	Preferred Stock Series A [Member]	Series A A Preferred Stock [Member]	Series N C Preferred Stock [Member]	Common Stock [Member]	Series M Preferred Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Contributed Capital [Member]	Total
Beginning balance, value at Sep. 30, 2020	$ 38,177	$ 5		$ 160,498	$ 4,400	$ 8,313,876	$ (16,583,666)	$ 731,711	$ (7,334,998)
Beginning balance, Shares at Sep. 30, 2020	381,768,689	50,000		1,605,000,246	44,000,000
Shares issued for Debt				$ 5,773		(2,021)			3,752
Shares issued for Debt, Shares				57,726,183
Shares issued for Interest				$ 2,234		(782)			1,452
Shares Issued For Interest, Shares				22,339,663
Shares issued for Debt				$ 6,001		(2,101)			3,900
Shares issued for Debt, Shares				60,007,919
Shares issued for Interest				$ 2,393		(838)			1,555
Shares Issued For Interest, Shares				23,926,234
Shares issued for Debt				$ 6,083		1,217			7,300
Shares issued for Debt, Shares				60,834,498
Shares issued for Interest				$ 2,619		523			3,142
Shares Issued For Interest, Shares				26,185,501
Shares issued for Debt				$ 330		99			429
Shares issued for Debt, Shares				3,300,000
Shares issued for Interest				$ 182		54			236
Shares issued for Interest, Shares				1,819,077
Shares issued for Fees				$ 123		36			159
Shares issued for Fees, shares				1,228,077
Shares issued for Debt				$ 6,200		(2,170)			4,030
Shares issued for Debt, Shares				62,003,571
Shares issued for Interest				$ 2,616		(916)			1,700
Shares issued for Interest, Shares				26,155,352
Shares issued for Debt				$ 6,833		1,367			8,200
Shares Issued for Debt, Shares				68,333,539
Shares issued for Interest				$ 1,488		212			1,700
Shares issued for Interest, Shares				14,883,378
Shares issued for Debt	$ 2,000					11,000			13,000
Shares Issued for Debt, Shares	20,000,437
Shares issued for Interest	$ 1,238					6,808			8,046
Shares issued for Interest, Shares	12,378,732
Shares issued for Debt				$ 8,889		7,111			16,000
Shares Issued for Debt, Shares				88,888,889
Shares issued for Interest				$ 1,956		1,294			3,250
Shares issued for Interest, Shares				19,555,555
Shares issued for Debt				$ 8,200		(2,870)			5,330
Shares Issued for Debt, Shares				82,004,603
Shares issued for Interest				$ 3,583		(1,254)			2,329
Shares issued for Interest, Shares				35,832,781
Additions to Contributed Capital Quarter ended 3/31/2021								1,865	1,865
Net Income							1,666,367		1,666,367
Ending balance, value at Dec. 31, 2020	$ 41,415	$ 5		$ 226,001	$ 4,400	8,330,646	(14,917,299)	733,576	(5,581,256)
Ending balance, Shares at Dec. 31, 2020	414,147,858	50,000		2,260,025,066	44,000,000
Shares issued for Debt				$ 8,590		(3,436)			5,154
Shares issued for Debt, Shares				85,900,000
Shares issued for Interest				$ 8,800		(4,400)			4,400
Shares Issued For Interest, Shares				88,000,000
Shares issued for Debt				$ 7,143		22,857			30,000
Shares issued for Debt, Shares				71,430,421
Shares issued for Interest				$ 1,133		3,625			4,758
Shares Issued For Interest, Shares				11,328,865
Shares issued for Debt				$ 8,093		(2,833)			5,260
Shares issued for Debt, Shares				80,928,505
Shares issued for Interest				$ 3,834		(1,342)			2,492
Shares Issued For Interest, Shares				38,341,033
Shares issued for Debt				$ 6,718		(3,361)			3,357
Shares issued for Debt, Shares				67,175,355
Shares issued for Interest				$ 882		(441)			441
Shares issued for Interest, Shares				8,824,645
Shares issued for Debt				$ 1,667		(667)			1,000
Shares issued for Debt, Shares				16,666,667
Shares issued for Interest				$ 9,583		(3,833)			5,750
Shares issued for Interest, Shares				95,833,333
Shares issued for Debt				$ 6,832		(3,417)			3,415
Shares Issued for Debt, Shares				68,319,520
Shares issued for Interest				$ 168		(84)			84
Shares issued for Interest, Shares				1,680,480
Shares issued for Debt				$ 3,852		(1,927)			1,925
Shares Issued for Debt, Shares				38,519,260
Shares issued for Interest				$ 148		(74)			74
Shares issued for Interest, Shares				1,480,740
Additions to Contributed Capital Quarter ended 3/31/2021								250	250
Net Income							442,183		442,183
Ending balance, value at Mar. 31, 2021	$ 41,415	$ 5	$ 0	$ 293,444	$ 4,400	8,331,313	(14,475,117)	733,826	(5,070,713)
Ending balance, Shares at Mar. 31, 2021	414,147,858	50,000	0	2,934,453,890	44,000,000
Shares issued for Debt				$ 8,421		(5,310)			3,111
Shares issued for Debt, Shares				84,214,968
Shares issued for Interest				$ 79		(30)			49
Shares Issued For Interest, Shares				785,032
Preferred Shares issued for Services			$ 1						1
Preferred Shares issued for Services, Shares			10,000
Shares issued for Debt				$ 2,639		16,361			19,000
Shares issued for Debt, Shares				26,389,990
Shares issued for Interest				$ 658		4,078			4,736
Shares Issued For Interest, Shares				6,578,052
Shares issued for Debt				$ 5,850		(2,340)			3,510
Shares issued for Debt, Shares				58,502,448
Shares issued for Interest				$ 2,513		(1,005)			1,508
Shares Issued For Interest, Shares				25,134,385
Shares issued for Debt				$ 9,754		(3,414)			6,340
Shares issued for Debt, Shares				97,542,355
Shares issued for Interest				$ 4,891		(1,712)			3,179
Shares issued for Interest, Shares				48,909,645
Shares issued for Debt				$ 3,815		(1,527)			2,288
Shares issued for Debt, Shares				38,145,154
Shares issued for Interest				$ 1,134		(454)			680
Shares issued for Interest, Shares				11,336,846
Shares issued for Debt				$ 8,995		(4,757)			4,238
Shares Issued for Debt, Shares				89,950,579
Shares issued for Interest				$ 36		(19)			17
Shares issued for Interest, Shares				360,821
Shares issued for Debt				$ 6,026		40,974			47,000
Shares Issued for Debt, Shares				60,257,055
Shares issued for Interest				$ 1,050		7,139			8,189
Shares issued for Interest, Shares				10,498,830
Shares issued for Debt				$ 12,642		(4,987)			7,655
Shares Issued for Debt, Shares				126,423,649
Shares issued for Interest				$ 3,739		(1,475)			2,264
Shares issued for Interest, Shares				37,390,351
Shares issued for Debt				$ 2,445		19,555			22,000
Shares Issued for Debt, Shares				24,445,152
Shares issued for Interest				$ 434		3,471			3,905
Shares issued for Interest, Shares				4,339,015
Shares issued for Debt				$ 2,179		(763)			1,416
Shares Issued for Debt, Shares				21,792,903
Shares issued for Interest				$ 1,122		(393)			729
Shares issued for Interest, Shares				11,219,652
Shares issued for Debt				$ 1,827		(640)			1,187
Shares Issued for Debt, Shares				18,271,120
Shares issued for Interest				$ 948		(332)			616
Shares issued for Interest, Shares				9,481,896
Shares issued for Debt				$ 3,377		(1,351)			2,026
Shares Issued for Debt, Shares				33,772,000
Contributed Capital Quarter Ended June 30, 2021								2,500	2,500
Net Income							(7,489,115)		(7,489,115)
Ending balance, value at Jun. 30, 2021	$ 41,415	$ 5	$ 1	$ 378,018	$ 4,400	8,392,382	(21,964,232)	736,326	(12,411,685)
Ending balance, Shares at Jun. 30, 2021	414,147,858	50,000	10,000	3,780,195,788	44,000,000
Beginning balance, value at Sep. 30, 2021	$ 43,200	$ 5	$ 1	$ 435,054	$ 4,400	8,644,037	(23,348,900)	736,326	(13,485,877)
Beginning balance, Shares at Sep. 30, 2021	431,998,817	50,000	10,000	4,350,554,514	44,000,000
Shares issued for Debt				$ 1,000		99,000			100,000
Shares issued for Debt, Shares				10,000,000
Shares issued for Interest				$ 267		26,395			26,662
Shares Issued For Interest, Shares				2,666,200
Shares issued for Debt				$ 1,000		99,000			100,000
Shares issued for Debt, Shares				10,000,000
Shares issued for Interest				$ 388		38,449			38,837
Shares Issued For Interest, Shares				3,883,700
Shares issued for Debt				$ 602		49,398			50,000
Shares issued for Debt, Shares				6,022,971
Shares issued for Interest				$ 236		19,367			19,603
Shares Issued For Interest, Shares				2,361,366
Shares issued for Debt				$ 1,550		48,450			50,000
Shares issued for Debt, Shares				15,503,953
Shares issued for Interest				$ 576		17,999			18,575
Shares issued for Interest, Shares				5,759,719
Shares issued for Debt				$ 995		31,080			32,075
Shares issued for Debt, Shares				9,945,768
Shares issued for Interest				$ 2,326		72,674			75,000
Shares issued for Interest, Shares				23,255,888
Shares issued for Debt				$ 100		24,900			25,000
Shares Issued for Debt, Shares				1,000,016
Shares issued for Interest				$ 775		24,225			25,000
Shares issued for Interest, Shares				7,751,973
Shares issued for Debt	$ 400					49,600			50,000
Shares Issued for Debt, Shares	4,000,047
Shares issued for Interest				$ 321		10,035			10,356
Shares issued for Interest, Shares				3,211,178
Shares issued for Debt				$ 1,026		98,974			100,000
Shares Issued for Debt, Shares				10,256,427
Shares issued for Interest				$ 36		8,847			8,883
Shares issued for Interest, Shares				355,326
Shares issued for Debt				$ 842		39,158			40,000
Shares Issued for Debt, Shares				8,421,053
Shares issued for Interest	$ 187					23,182			23,369
Shares issued for Interest, Shares	1,869,542
Shares issued for Debt				$ 625		49,375			50,000
Shares Issued for Debt, Shares				6,250,082
Shares issued for Interest				$ 238		18,774			19,012
Shares issued for Interest, Shares				2,376,531
Shares issued for Interest				$ 408		39,400			39,808
Shares issued for Interest, Shares				4,082,878
Shares issued for Debt				$ 7,248		3,716			10,964
Shares Issued for Debt, Shares				72,476,800
Shares issued for Interest				$ 299		13,893			14,192
Shares issued for Interest, Shares				2,987,789
Shares issued for Debt				$ 100		24,900			25,000
Shares Issued for Debt, Shares				1,000,014
Shares issued for Interest				$ 46		11,481			11,527
Shares issued for Interest, Shares				461,086
Shares issued for Debt				$ 240		59,760			60,000
Shares Issued for Debt, Shares				2,400,000
Shares issued for Interest				$ 102		25,338			25,440
Shares issued for Interest, Shares				1,017,600
Shares issued for Debt	$ 100					24,900			25,000
Shares issued for debt, Shares	1,000,000
Shares issued for Interest	$ 43					10,583			10,625
Shares issued for Interest, Shares	425,000
Net Income							2,644,980		2,644,980
Ending balance, value at Dec. 31, 2021	$ 43,929	$ 5	$ 1	$ 456,399	$ 4,400	9,706,891	(20,703,920)		(9,755,969)
Ending balance, Shares at Dec. 31, 2021	439,293,406	50,000	10,000	4,564,002,832	44,000,000
Shares issued for Debt				$ 879		47,541			48,420
Shares issued for Debt, Shares				8,790,790
Shares issued for Interest				$ 721		38,987			39,708
Shares Issued For Interest, Shares				7,209,210
Net Income							(67,081,589)		(67,081,589)
Ending balance, value at Mar. 31, 2022	$ 43,929	$ 5	$ 1	$ 457,999	$ 4,400	9,793,419	(87,785,509)		(76,749,430)
Ending balance, Shares at Mar. 31, 2022	439,293,406	50,000	10,000	4,580,002,832	44,000,000
Shares issued for Debt				$ 3,969		214,648			218,617
Shares issued for Debt, Shares				39,691,174
Shares issued for Interest				$ 31		1,670			1,701
Shares Issued For Interest, Shares				308,826
Shares issued for Debt				$ 9,973		540,188			550,161
Shares issued for Debt, Shares				99,728,094
Shares issued for Interest				$ 27		1,473			1,500
Shares Issued For Interest, Shares				271,906
Shares issued for Debt				$ 10,000		324,800			334,800
Shares issued for Debt, Shares				100,000,000
Shares issued for Debt				$ 10,000		324,800			334,800
Shares issued for Debt, Shares				100,000,000
Net Income							66,958,167		66,958,167
Ending balance, value at Jun. 30, 2022	$ 43,929	$ 5	$ 1	$ 491,999	$ 4,400	$ 11,200,998	$ (20,827,342)		$ (8,349,684)
Ending balance, Shares at Jun. 30, 2022	439,293,406	50,000	10,000	4,920,002,832	44,000,000

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	9 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net Income (loss)	$ 2,521,557	$ (5,380,566)
Adjustments to reconcile net Income to net cash
Common Stock issued for Expenses		159
Preferred Stock issued as compensation		1
Increase (Decrease) in Interest expense attributable to amortization of Discount	66,631	47,063
Increase (Decrease) in Accounts Payable	(62,705)	(10,263)
(Increase) Decrease in Accounts Receivable	(82,275)	(82,273)
Increase (Decrease) in accrued Expenses	78,996	275,388
(Increase) Decrease in Prepaid Expenses	20,343	28
Increase(Decrease) in Contributed Capital		4,615
Increase ( Decrease)  in Derivative Expense	(3,238,473)	4,546,174
Increase ( Decrease) in Unearned Income	(93,877)	1,875,794
Increase ( Decrease) in Penalties	300,000
(Increase( Decrease in Notes Receivable		(5,396)
(Increase( Decrease in Accrued Interest Receivable	(399)	(96)
Securities accepted as compensation		(1,850,000)
Increase (Decrease) in Loss on Sale of Investment Securities		206,900
Unrealized Loss(Gain) on Investment Securities	(31,433)	308,550
Net Cash Provided by (Used in) Operating	(521,634)	(63,921)
Cash Flows from Investment Activities
Increase(Decrease) in Sale of Investment Securities		300,000
Net Cash Provided By Investment Activities		300,000
CASH FLOWS FROM FINANCING ACTIVITIES
( Decrease) in Notes Payable		(47,900)
Increase (Decrease) in Convertible Notes Payable	(94,535)
Net Cash Provided by (Used in) Financing Activities	(94,535)	(47,900)
Net Increase (Decrease) in Cash	(616,169)	188,179
Cash at Beginning of Period	727,162	0
Cash at End of Period	110,993	188,179
Supplemental Disclosure of Noncash investing and financing activities:
Common shares Issued for Debt	2,197,762	218,723
Preferred Shares Issued for Debt	75,000	13,000
Cash Paid for Interest	27,473	0
Common shares Issued for Interest	309,379	59,592
Preferred Shares issued for Interest	$ 33,994	$ 8,046

ORGANIZATION AND SUMMARY OF SIG

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The Company was organized April 24, 2012 under the laws of the State of Nevada The Company intends to engage primarily in the development of regenerative medical applications which we intend to license from other entities up to the point of successful completion of Phase I and or Phase II clinical trials after which we would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials. The Company is currently engaged in actively identifying small molecules that inhibit or express NR2F6 leading to immune cell activation for oncology applications and immune cell suppression for autoimmune disease. The Company is in the early stages of development of its proposed products and therapies. The Company will be required to obtain approval from the FDA in order to market any of The Company’s products or therapies. No approval has been granted by the FDA for the marketing and sale of any of the Company’s products and therapies and no assurance may be given that any of the Company’s products or therapies will be granted such approval. The Company’s current plans include the development of regenerative medical applications up to the point of successful completion of Phase I and/ or Phase II clinical trials after which the Company would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials. The Company can provide no assurance that the Company will be able to sell or license any product or that, if such product is sold or licensed, such sale or license will be on terms favorable to the Company. A. BASIS OF ACCOUNTING The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a September 30 year-end. B. PRINCIPLES OF CONSOLIDATION The consolidated financial statements include the accounts of KCL Therapeutics, Inc., a Nevada corporation and wholly owned subsidiary of Regen. Significant inter-company transactions have been eliminated. The Company analyzes the conversion feature of Convertible Notes for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model. The Black Scholes pricing model used to determine the Derivative Liability on convertible notes issued by the Company in which an embedded derivative is recognized as of June 30, 2022 utilized the following inputs: Schedule of Derivative Liability Risk Free Interest Rate 2.98 % Expected Term .( 0.5 ) – ( 2.88 ) Yrs Expected Volatility 855.05 % Expected Dividends H. INCOME TAXES The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date. The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of September 30, 2021 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future. The Company generated a deferred tax credit through net operating loss carry forward. However, a valuation allowance of 100 % has been established. Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19. I. BASIC EARNINGS (LOSS) PER SHARE The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, “Earnings Per Share”, which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception. Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding. ADVERTISING Costs associated with advertising are charged to expense as incurred. Advertising expenses were $ 0 for the quarters ended June 30,2021 and June 30, 2022. K. NOTES RECEIVABLE Notes receivable are stated at cost, less impairment, if any. As of June 30,2022 the Company has the following Notes Receivable Schedule of notes receivable Zander Therapeutics, Inc. $ 5,396 $5,396 owed to the Company by Zander Therapeutics, Inc. bears simple interest at 10% and is due upon the demand of the Company. L. REVENUE RECOGNITION Sales of products and related costs of products sold are recognized when: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred; (iii) the price is fixed or determinable; and (iv) collectability is reasonably assured. These terms are typically met upon the prepayment or invoicing and shipment of products. The Company determines the amount and timing of royalty revenue based on its contractual agreements with intellectual property licensees. The Company recognizes royalty revenue when earned under the terms of the agreements and when the Company considers realization of payment to be probable. Where royalties are based on a percentage of licensee sales of royalty-bearing products, the Company recognizes royalty revenue by applying this percentage to the Company’s estimate of applicable licensee sales. The Company bases this estimate on an analysis of each licensee’s sales results. Where warranted, revenue from licensees for contractual obligations such as License Initiation Fees are recognized upon satisfaction of all conditions required to be satisfied in order for that revenue to have been earned by the Company. M. INTEREST RECEIVABLE Interest receivable is stated at cost, less impairment, if any.

RECENT ACCOUNTING PRONOUNCEMENT

RECENT ACCOUNTING PRONOUNCEMENTS	9 Months Ended
	Jun. 30, 2022
Accounting Changes and Error Corrections [Abstract]
RECENT ACCOUNTING PRONOUNCEMENTS	NOTE 2. RECENT ACCOUNTING PRONOUNCEMENTS In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-10, which eliminated certain financial reporting requirements of companies previously identified as “Development Stage Entities” (Topic 915). The amendments in this ASU simplify accounting guidance by removing all incremental financial reporting requirements for development stage entities. The amendments also reduce data maintenance and, for those entities subject to audit, audit costs by eliminating the requirement for development stage entities to present inception-to-date information in the statements of income, cash flows, and shareholder equity. Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity’s financial statements have not yet been issued (public business entities) or made available for issuance (other entities). Upon adoption, entities will no longer present or disclose any information required by Topic 915. The Company has adopted this standard. As of the fiscal year ending September 30, 2019 the Company has adopted Accounting Standards Update 2014-09, Revenue from Contracts with Customers (Topic 606). The guidance in this Update supersedes the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific guidance throughout the Industry Topics of the Codification. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. In June 2014, FASB issued Accounting Standards Update (ASU) No. 2014-12 Compensation — Stock Compensation (Topic 718), Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. A performance target in a share-based payment that affects vesting and that could be achieved after the requisite service period should be accounted for as a performance condition under Accounting Standards Codification (ASC) 718, Compensation — Stock Compensation. As a result, the target is not reflected in the estimation of the award’s grant date fair value. Compensation cost would be recognized over the required service period, if it is probable that the performance condition will be achieved. The guidance is effective for annual periods beginning after 15 December 2015 and interim periods within those annual periods. Early adoption is permitted. The Company has reviewed the applicable ASU and has not, at the current time, quantified the effects of this pronouncement, however it believes that there will be no material effect on the consolidated financial statements. In August 2014, FASB issued Accounting Standards Update (ASU) No. 2014-15 Preparation of Financial Statements – Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. Under generally accepted accounting principles (GAAP), continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity’s liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. If and when an entity’s liquidation becomes imminent, financial statements should be prepared under the liquidation basis of accounting in accordance with Subtopic 205-30, Presentation of Financial Statements—Liquidation Basis of Accounting. Even when an entity’s liquidation is not imminent, there may be conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern. In those situations, financial statements should continue to be prepared under the going concern basis of accounting, but the amendments in this Update should be followed to determine whether to disclose information about the relevant conditions and events. The amendments in this Update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company will evaluate the going concern considerations in this ASU, however, at the current period, management does not believe that it has met the conditions which would subject these financial statements for additional disclosure. On January 31, 2013, the FASB issued Accounting Standards Update [ASU] 2013-01, entitled Clarifying the Scope of Disclosures about Offsetting Assets and Liabilities. The guidance in ASU 2013-01 amends the requirements in the FASB Accounting Standards Codification [FASB ASC] Topic 210, entitled Balance Sheet. The ASU 2013-01 amendments to FASB ASC 210 clarify that ordinary trade receivables and receivables in general are not within the scope of ASU 2011-11, entitled Disclosure about Offsetting Assets and Liabilities, where that ASU amended the guidance in FASB ASC 210. As those disclosures now are modified with the ASU 2013-01 amendments, the FASB ASC 210 balance sheet offsetting disclosures now clearly are applicable only where reporting entities are involved with bifurcated embedded derivatives, repurchase agreements, reverse repurchase agreements, and securities borrowing and lending transactions that either are offset using the FASB ASC 210 or 815 requirements, or that are subject to enforceable master netting arrangements or similar agreements. ASU 2013-01 is effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. The adoption of this ASU is not expected to have a material impact on our financial statements. On February 28, 2013, the FASB issued Accounting Standards Update [ASU] 2013-04, entitled Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation Is Fixed at the Reporting Date. The ASU 2013-04 amendments add to the guidance in FASB Accounting Standards Codification [FASB ASC] Topic 405, entitled Liabilities and require reporting entities to measure obligations resulting from certain joint and several liability arrangements where the total amount of the obligation is fixed as of the reporting date, as the sum of the following: The amount the reporting entity agreed to pay on the basis of its arrangement among co-obligors. Any additional amounts the reporting entity expects to pay on behalf of its co-obligors. While early adoption of the amended guidance is permitted, for public companies, the guidance is required to be implemented in fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments need to be implemented retrospectively to all prior periods presented for obligations resulting from joint and several liability arrangements that exist at the beginning of the year of adoption. The adoption of ASU 2013-04 is not expected to have a material effect on the Company’s operating results or financial position. On April 22, 2013, the FASB issued Accounting Standards Update [ASU] 2013-07, entitled Liquidation Basis of Accounting. With ASU 2013-07, the FASB amends the guidance in the FASB Accounting Standards Codification [FASB ASC] Topic 205, entitled Presentation of Financial Statements. The amendments serve to clarify when and how reporting entities should apply the liquidation basis of accounting. The guidance is applicable to all reporting entities, whether they are public or private companies or not-for-profit entities. The guidance also provides principles for the recognition of assets and liabilities and disclosures, as well as related financial statement presentation requirements. The requirements in ASU 2013-07 are effective for annual reporting periods beginning after December 15, 2013, and interim reporting periods within those annual periods. Reporting entities are required to apply the requirements in ASU 2013-07 prospectively from the day that liquidation becomes imminent. Early adoption is permitted. The adoption of ASU 2013-07 is not expected to have a material effect on the Company’s operating results or financial position. In January 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (ASU) 2016-01, which amends the guidance in U.S. GAAP on the classification and measurement of financial instruments. Changes to the current guidance primarily affect the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, the ASU clarifies guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The new standard is effective for fiscal years and interim periods beginning after December 15, 2017, and upon adoption, an entity should apply the amendments by means of a cumulative-effect adjustment to the balance sheet at the beginning of the first reporting period in which the guidance is effective. Early adoption is not permitted except for the provision to record fair value changes for financial liabilities under the fair value option resulting from instrument-specific credit risk in other comprehensive income. The Company adopted ASU 2016-01 as of the fiscal year ending September 30, 2019. In August 2020, FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity; Own Equity (“ASU 2020-06”), as part of its overall simplification initiative to reduce costs and complexity of applying accounting standards while maintaining or improving the usefulness of the information provided to users of financial statements. Among other changes, the new guidance removes from GAAP separation models for convertible debt that require the convertible debt to be separated into a debt and equity component, unless the conversion feature is required to be bifurcated and accounted for as a derivative or the debt is issued at a substantial premium. As a result, after adopting the guidance, entities will no longer separately present such embedded conversion features in equity, and will instead account for the convertible debt wholly as debt. The new guidance also requires use of the “if-converted” method when calculating the dilutive impact of convertible debt on earnings per share, which is consistent with the Company’s current accounting treatment under the current guidance. The guidance is effective for financial statements issued for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, but only at the beginning of the fiscal year. The Company has adopted ASU 2020-06 as of the Fiscal Year ending September 30, 2022. A variety of proposed or otherwise potential accounting standards are currently under study by standard setting organizations and various regulatory agencies. Due to the tentative and preliminary nature of those proposed standards, the Company’s management has not determined whether implementation of such standards would be material to its financial statements.

GOING CONCERN

GOING CONCERN	9 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	NOTE 3. GOING CONCERN The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company generated net losses of $ 20,827,342 during the period from April 24, 2012 (inception) through June 30, 2022. This condition raises substantial doubt about the Company’s ability to continue as a going concern. The Company’s continuation as a going concern is dependent on its ability to meet its obligations, to obtain additional financing as may be required and ultimately to attain profitability. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Management plans to raise additional funds by offering securities for cash. Management has yet to decide what type of offering the Company will use or how much capital the Company will raise.

NOTES PAYABLE

NOTES PAYABLE	9 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
NOTES PAYABLE	NOTE 4. NOTES PAYABLE (a) RELATED PARTY Schedule of notes payable related party As of June 30, 2022 David Koos $ 227 Total: $ 227 $ 227 lent to the Company by David Koos is due and payable at the demand of the holder and bears simple interest at a rate of 15 % per annum.

CONVERTIBLE NOTES PAYABLE

CONVERTIBLE NOTES PAYABLE	9 Months Ended
	Jun. 30, 2022
Convertible Notes Payable
CONVERTIBLE NOTES PAYABLE	NOTE 5. CONVERTIBLE NOTES PAYABLE On March 8, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $ 100,000 for consideration consisting of $ 100,000 cash. The Note pays simple interest in the amount of 8 % per annum . The maturity of the Note is three years from the issue date. The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock, as such Common Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Common Stock shall hereafter be changed or reclassified pursuant to the following terms and conditions: (a) For the period beginning on the Issue Date and ending 365 days subsequent to the Issue Date (“Year 1”) a 50% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater). (b) For the period beginning one day subsequent to the final day of Year One and ending 365 days subsequent to Year One (“Year 2”) a 35% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater). (c) For the period beginning one day subsequent to the final day of Year 2 and ending 365 days subsequent to Year 2 (“Year 3”) a 25% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater). (d) “Trading Price” means the closing bid price on the Over-the-Counter Bulletin Board, or applicable trading market (the “OTCQB”) as reported by a reliable reporting service (“Reporting Service”) designated by the Lender (i.e. Bloomberg) or, if the OTCQB is not the principal trading market for such security, the closing bid price of such security on the principal securities exchange or trading market where such security is listed or traded or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the “pink sheets” by the National Quotation Bureau, Inc. If the Trading Price cannot be calculated for such security on such date in the manner provided above, the Trading Price shall be the fair market value as mutually determined by the Company and the Lender. “Trading Day” shall mean any day on which the Common Stock is tradable for any period on the OTCQB, or on the principal securities exchange or other securities market on which the Common Stock is then being traded. “Trading Volume” shall mean the number of shares traded on such Trading Day as reported by such Reporting Service. The Conversion Price shall be equitably adjusted for stock splits, stock dividends, rights offerings, combinations, recapitalization, reclassifications, extraordinary distributions and similar events by the Company relating to the Lender’s securities. The Company shall have the right, exercisable on not less than five (5) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. Upon closing of a Transaction Event the Lender shall receive 0 .10% ( one tenth of one percent)of the consideration actually received by the Company from an unaffiliated third party as a result of the closing of a Transaction Event. “Transaction Event” shall mean either of: (a) The sale by the Company of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party (b) The granting of a license by the Company to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize the Company’s proprietary NR2F6 intellectual property As of June 30, 2022 $ 100,000 of the principal amount of the Note remains outstanding. On April 6, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $ 50,000 for consideration consisting of $ 50,000 cash. The Note pays simple interest in the amount of 8 % per annum . The maturity of the Note is three years from the issue date. The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock, as such Common Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Common Stock shall hereafter be changed or reclassified pursuant to the following terms and conditions: (a) For the period beginning on the Issue Date and ending 365 days subsequent to the Issue Date (“Year 1”) a 50% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater). (b) For the period beginning one day subsequent to the final day of Year One and ending 365 days subsequent to Year One (“Year 2”) a 35% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater). (c) For the period beginning one day subsequent to the final day of Year 2 and ending 365 days subsequent to Year 2 (“Year 3”) a 25% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater). (d) “Trading Price” means the closing bid price on the Over-the-Counter Bulletin Board, or applicable trading market (the “OTCQB”) as reported by a reliable reporting service (“Reporting Service”) designated by the Lender (i.e. Bloomberg) or, if the OTCQB is not the principal trading market for such security, the closing bid price of such security on the principal securities exchange or trading market where such security is listed or traded or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the “pink sheets” by the National Quotation Bureau, Inc. If the Trading Price cannot be calculated for such security on such date in the manner provided above, the Trading Price shall be the fair market value as mutually determined by the Company and the Lender. “Trading Day” shall mean any day on which the Common Stock is tradable for any period on the OTCQB, or on the principal securities exchange or other securities market on which the Common Stock is then being traded. “Trading Volume” shall mean the number of shares traded on such Trading Day as reported by such Reporting Service. The Conversion Price shall be equitably adjusted for stock splits, stock dividends, rights offerings, combinations, recapitalization, reclassifications, extraordinary distributions and similar events by the Company relating to the Lender’s securities. Upon closing of a Transaction Event the Lender shall receive 0 .10% ( one tenth of one percent)of the consideration actually received by the Company from an unaffiliated third party as a result of the closing of a Transaction Event. “Transaction Event” shall mean either of: (a) The sale by the Company of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party (b) The granting of a license by the Company to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize the Company’s proprietary NR2F6 intellectual property As of June 20, 2022 $ 50,000 of the principal amount of the Note remains outstanding. On October 31, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $ 50,000 for consideration consisting of $ 50,000 cash. The Note pays simple interest in the amount of 10 % per annum . The maturity of the Note is two years from the issue date. The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $ 0.0125 per share. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. As of June 30, 2022 $ 50,000 of the principal amount of the Note remains outstanding. On October 31, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $ 50,000 for consideration consisting of $ 50,000 cash. The Note pays simple interest in the amount of 10 % per annum . The maturity of the Note is two years from the issue date. The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. As of June 30, 2022 $ 50,000 of the principal amount of the Note remains outstanding. On October 31, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $ 50,000 for consideration consisting of $ 50,000 cash. The Note pays simple interest in the amount of 10 % per annum . The maturity of the Note is two years from the issue date. The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share. As of June 30 ,2021 $ 50,000 of the principal amount of the Note remains outstanding. March 13, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $ 50,000 for consideration consisting of $ 50,000 cash. The Note pays simple interest in the amount of 10 % per annum . The maturity of the Note is February 24, 2020. All or part of the principal is convertible at any time at the demand of the Lender into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $0.0125 per common share. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. In the event that that the Company exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the Note into Common shares of the Company. The warrants shall have a strike price of $0.05 per share. The warrants shall be exercisable: In the event that the Company exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have been prepaid by the Company(“Prepayment Date”) In the event , part of the outstanding and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close of business on the three (3) month anniversary of the Maturity Date of the Note. As of June 30, 2022 $ 50,000 of the principal amount of the Note remains outstanding. The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $ 177,778 was recognized by the Company as of June 30, 2022. On March 31, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $ 50,000 for consideration consisting of $ 50,000 cash. The Note pays simple interest in the amount of 10 % per annum . The maturity of the Note is March 31, 2020. All or part of the principal is convertible at any time at the demand of the Lender into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $0.0125 per common share. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. In the event that that the Company exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the Note into Common shares of the Company. The warrants shall have a strike price of $0.05 per share. In the event that the Company exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have been prepaid by the Company(“Prepayment Date”) In the event part of the outstanding and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close of business on the three (3) month anniversary of the Maturity Date of the Note. As of June 30 ,2022 $ 50,000 of the principal amount of the Note remains outstanding. The Company analyzed the conversion feature of the Note for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $ 177,778 was recognized by the Company as of June 30, 2022. On April 19, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $ 50,000 for consideration consisting of $ 50,000 cash. The Note pays simple interest in the amount of 10 % per annum . The maturity of the Note is April 19, 2020. All or part of the principal is convertible at any time at the demand of the Lender into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $0.0125 per common share. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. In the event that that the Company exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the Note into Common shares of the Company. The warrants shall have a strike price of $0.05 per share. The warrants shall be exercisable: In the event that the Company exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have been prepaid by the Company(“Prepayment Date”) In the event , part of the outstanding and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close of business on the three (3) month anniversary of the Maturity Date of the Note As of June 30, 2022 $ 50,000 of the principal amount of the Note remains outstanding. The Company analyzed the conversion feature of the Note for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $ 177,778 was recognized by the Company as of June 30, 2022. 200,000 for consideration consisting of $ 200,000 cash. The Note pays simple interest in the amount of 10 % per annum . The maturity of the Note is May 5, 2020. The Note is convertible into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $0.025 per common share as of the date which is the earlier of: (i) One day subsequent to the execution of an agreement to a transaction whose completion would result in a “Change of Control” of the Company. For purposes of this Note, a Change of Control shall be defined as any transaction or series of transactions, whether by merger, sale of substantially all of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding stock of the relevant entity in which the members of the Board of Directors immediately preceding the closing of the Change of Control transaction no longer constitute a majority of the Board of Directors of the surviving entity following the closing of such transaction. ii) One day subsequent to the commencement, in compliance with applicable law, of a broad solicitation by a third party to purchase a majority percentage of the Company’s outstanding equity securities for a limited period of time contingent on shareholders of the Company tendering a fixed number of their equity securities (“Tender Offer”). (iii) That date which is twenty four (24) months subsequent to the date of execution of this Note. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. In the event that that the Company exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the Note into Common shares of the Company. The warrants shall have a strike price of $0.05 per share. The warrants shall be exercisable: In the event that the Company exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have been prepaid by the Company(“Prepayment Date”) In the event , part of the outstanding and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close of business on the three (3) month anniversary of the Maturity Date of the Note As of June 30, 2022 $ 200,000 of the principal amount of the Note remains outstanding. The Company analyzed the conversion feature of the Note for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $ 711,111 was recognized by the Company as of June 30, 2022. On June 26, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $ 150,000 for consideration consisting of $ 150,000 cash. The Note pays simple interest in the amount of 10 % per annum . The maturity of the Note is June 16, 2020. The Note may be converted into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $0.025 per common share as of the date which is the earlier of: (i) One day subsequent to the execution of an agreement to a transaction whose completion would result in a “Change of Control” of the Company or KCL Therapeutics. For purposes of this Note, a Change of Control shall be defined as any transaction or series of transactions, whether by merger, sale of substantially all of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding stock of the relevant entity in which the members of the Board of Directors immediately preceding the closing of the Change of Control transaction no longer constitute a majority of the Board of Directors of the surviving entity following the closing of such transaction. (ii) One day subsequent to the commencement, in compliance with applicable law, of a broad solicitation by a third party to purchase a majority percentage of the Company’s outstanding equity securities for a limited period of time contingent on shareholders of the Company tendering a fixed number of their equity securities (“Tender Offer”). (iv) One day subsequent to a “Transaction Event”) (a) The sale by the Company or by KCL Therapeutics , Inc. of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party (b) The granting of a license by the Company or by KCL Therapeutics , Inc to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize the Company’s proprietary NR2F6 intellectual property (v) That date which is twenty four (24) months subsequent to the date of execution of this Note. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. In the event that that the Company exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the Note into Common shares of the Company. The warrants shall have a strike price of $0.025 per share. The warrants shall be exercisable: In the event that the Company exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have been prepaid by the Company(“Prepayment Date”) In the event , part of the outstanding and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close of business on the three (3) month anniversary of the Maturity Date of the Note As of June 30, 2022 $ 150,000 of the principal amount of the Note remains outstanding. The Company analyzed the conversion feature of the Note for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $ 533,333 was recognized by the Company as of June 30 2022. On September 25, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $ 50,000 for consideration consisting of $ 50,000 cash. The Note pays simple interest in the amount of 10 % per annum. The maturity of the Note is September 25, 2020. The Note may be converted into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $0.0125 per common share as of the date which is the earlier of: (i) One day subsequent to the execution of an agreement to a transaction whose completion would result in a “Change of Control” of the Company or KCL Therapeutics. For purposes of this Note, a Change of Control shall be defined as any transaction or series of transactions, whether by merger, sale of substantially all of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding stock of the relevant entity in which the members of the Board of Directors immediately preceding the closing of the Change of Control transaction no longer constitute a majority of the Board of Directors of the surviving entity following the closing of such transaction. (ii) One day subsequent to the commencement, in compliance with applicable law, of a broad solicitation by a third party to purchase a majority percentage of the Company’s outstanding equity securities for a limited period of time contingent on shareholders of the Company tendering a fixed number of their equity securities (“Tender Offer”). (iv) One day subsequent to a “Transaction Event”) Transaction Event” shall mean either of: (a) The sale by the Company or by KCL Therapeutics , Inc. of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party (b) The granting of a license by the Company or by KCL Therapeutics , Inc to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize the Company’s proprietary NR2F6 intellectual property (v) That date which is twenty four (24) months subsequent to the date of execution of this Note. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. In the event that that the Company exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the Note into Common shares of the Company. The warrants shall have a strike price of $0.025 per share. The warrants shall be exercisable: In the event that the Company exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have been prepaid by the Company (“Prepayment Date”) In the event , part of the outstanding and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close of business on the three (3) month anniversary of the Maturity Date of the Note As of June 30, 2022 $ 50,000 of the principal amount of the Note remains outstanding. The Company analyzed the conversion feature of the Note for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $ 177,778 was recognized by the Company as of June 30, 2022. 50,000 for consideration consisting of $ 50,000 cash. The Note pays simple interest in the amount of 10 % per annum. The maturity of the Note is October 3, 2020. The Note may be converted into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $0.025 per common share as of the date which is the earlier of: (i) One day subsequent to the execution of an agreement to a transaction whose completion would result in a “Change of Control” of the Company or KCL Therapeutics. For purposes of this Note, a Change of Control shall be defined as any transaction or series of transactions, whether by merger, sale of substantially all of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding stock of the relevant e

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	Jun. 30, 2022
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 6. RELATED PARTY TRANSACTIONS On June 23, 2015 the Company entered into an agreement (“Agreement”) with Zander Therapeutics, Inc. ( “Zander”) whereby The Company granted to Zander an exclusive worldwide right and license for the development and commercialization of certain intellectual property controlled by The Company (” License IP”) for non-human veterinary therapeutic use for a term of fifteen years. Zander is under common control with the Company. Pursuant to the Agreement, Zander shall pay to The Company one-time, non-refundable, upfront payment of one hundred thousand US dollars ($100,000) as a license initiation fee which must be paid within 90 days of June 23, 2015 and an annual non-refundable payment of one hundred thousand US dollars ($100,000) on July 15th, 2016 and each subsequent anniversary of the effective date of the Agreement. The abovementioned payments may be made, at Zander’s discretion, in cash or newly issued common stock of Zander. Pursuant to the Agreement, Zander shall pay to The Company royalties equal to four percent (4%) of the Net Sales , as such term is defined in the Agreement, of any Licensed Products, as such term is defined in the Agreement, in a Quarter. Pursuant to the Agreement, Zander will pay The Company ten percent (10%) of all consideration (in the case of in-kind consideration, at fair market value as monetary consideration) received by Zander from sublicensees ( excluding royalties from sublicensees based on Net Sales of any Licensed Products for which The Company receives payment pursuant to the terms and conditions of the Agreement). Zander is obligated pay to The Company minimum annual royalties of ten thousand US dollars ($10,000) payable per year on each anniversary of the Effective Date of this Agreement, commencing on the second anniversary of June 23, 2015. This minimum annual royalty is only payable to the extent that royalty payments made during the preceding 12-month period do not exceed ten thousand US dollars ($10,000). The Agreement may be terminated by The Company: If Zander has not sold any Licensed Product by ten years of the effective date of the Agreement or Zander has not sold any Licensed Product for any twelve (12) month period after Zander’s first commercial sale of a Licensed Product. The Agreement may be terminated by Zander with regard to any of the License IP if by five years from the date of execution of the Agreement a patent has not been granted by the United States patent and Trademark Office to The Company with regard to that License IP. The Agreement may be terminated by Zander with regard to any of the License IP if a patent that has been granted by the United States patent and Trademark Office to The Company with regard to that License IP is terminated. The Agreement may be terminated by either party in the event of a material breach by the other party. On December 17, 2018 Regen Biopharma, Inc.(“Licensor”) , KCL Therapeutics, Inc. (“Assignee”) and Zander Therapeutics, Inc. (“Licensee”) entered into a LICENSE ASSIGNMENT AND CONSENT AGREEMENT whereby, with regards to certain intellectual property which was assigned by Regen Biopharma, Inc.(“Assigned Properties”) to its wholly owned subsidiary KCL Therapeutics, Inc., Licensor hereby transfers and assigns to Assignee all rights, duties, and obligations of Licensor under the Agreement with respect to the Assigned Properties , and Assignee agrees to assume such duties and obligations thereunder and be bound to the terms of the Agreement with respect thereto. On December 16, 2019 Zander Therapeutics, Inc. (“Zander”), KCL Therapeutics, Inc. (“KCL”) and Regen Biopharma, Inc. (“Regen”) entered into an agreement (“Agreement”) whereby: 1) Zander shall return for cancellation 194,285,714 shares of the Series A Preferred stock of Regen (“Conversion Shares”) acquired by Zander through conversion of $340,000 of principal indebtedness of a $350,000 convertible note payable issued by Regen to Zander. Subsequent to this event the principal amount due to Zander by Regen pursuant to the Convertible Note shall be $350,000 which shall be applied pursuant to the Agreement. 2) A $35,000 one time charge due to Zander by Regen (“One Time Charge”) shall be applied pursuant to the Agreement. 3) $75,900 of principal indebtedness due to Regen by Zander and $4,328 of accrued but unpaid interest due by Regen to Zander shall be applied pursuant to the Agreement. No actions were taken by any of the parties to enforce the terms of the Agreement. On April 15, 2021 the Agreement was amended as follows so that the material terms and conditions shall be: a) Zander shall not return the Conversion shares for cancellation and the principal indebtedness of the aforementioned convertible note shall not reflect such return b) As of December 16, 2019 all principal and accrued interest payable by Regen to Zander on that date resulting from Promissory Notes issued by Regen to Zander shall be credited towards amounts due by Zander pursuant to that agreement, as amended, entered into by and between Zander and Regen on June 23, 2015 (“License Agreement”) whereby Regen granted to Zander an exclusive worldwide right and license for the development and commercialization of certain intellectual property controlled by Regen for non-human veterinary therapeutic use for a term of fifteen years and that License Assignment And Consent agreement entered into by and between Regen, KCL and Zander on December 17, 2018 whereby Regen transferred and assigned to KCL all rights, duties, and obligations of Regen under the License Agreement and KCL agreed to assume such duties and obligations thereunder and be bound to the terms of the License Agreement with respect thereto. Zander and Regen are under common control. On September 30, 2018 Regen Biopharma, Inc. (“Regen”) issued a convertible promissory note in the principal amount of $ 350,000 (“Note”) to Zander Therapeutics, Inc. (“Zander”). Consideration for the Note consisted of $350,000. A onetime interest charge of 10% of the principal amount shall be applied to the principal amount of the Note. The Note is due and payable 24 months from the effective date. Zander has the right, at any time after the September 30, 2018, at its election, to convert all or part of the outstanding and unpaid Principal Sum and accrued interest (and any other fees) into shares of fully paid and non-assessable shares of Series A Preferred stock of Regen as per this conversion formula: Number of shares receivable upon conversion equals the dollar conversion amount divided by the Conversion Price. The Conversion Price is the greater of $0.0001 or 60% of the lowest trade price in the 25 trading days previous to the conversion. Zander, at any time prior to selling all of the shares from a conversion, may, for any reason, rescind any portion, in whole or in part, of that particular conversion attributable to the unsold shares and have the rescinded conversion amount returned to the Principal Sum with the rescinded conversion shares returned to Regen. As of June 30, 2021, $ 10,000 of the principal amount of the Note remains outstanding. During the quarter ended June 30, 2021 Zander Therapeutics, Inc. issued a promissory note in the amount of $5,396 to the Company as consideration for expenses of Zander Therapeutics Inc., paid by the Company. The Note is payable on demand of the Holder and bears simple interest at 10% per annum. On October 8,2021 the Company entered into an agreement with Dr. Brian Koos, MD PhD whereby Dr. Brian Koos would provide services to the Company consisting of : a) Reviewing existing publications on research being conducted on Checkpoint NR2F6. b) Identifying the most promising applications for the Company’s technology c) Drafting a “white paper” on results for 1(b) d) Making introductions to known experts in appropriate fields identified in 1(b). Dr. Brian Koos is to be paid compensated $117,000 as total consideration for performing the abovementioned tasks. During the quarter ended December 31, 2021 Dr. Brian Koos was paid the amount of $80,275 and during the quarter ended March 31, 2022 Dr. Brian Koos was paid $36,975. Dr. Brian Koos is the brother of David Koos the Chairman and Chief Executive Officer of the Company. As of June 30, 2022 the Company is indebted to David R. Koos the Company’s sole officer and director in the amount of $ 227 . $ 227 lent to the Company by Koos is due and payable at the demand of the holder and bear simple interest at a rate of 15% per annum. During the quarter ended December 31, 2021 the Company paid $5,000 of rental expenses to the landlord of BST Partners as consideration to BST Partners for use of office space. BST Partners is controlled by David R. Koos the Chairman and Chief Executive Officer of the Company. On January 13, 2022 Regen Biopharma, Inc. entered into a sublease agreement with BST Partners (“BST”) whereby Regen Biopharma, Inc. would sublet office space located at 4700 Spring Street, Suite 304, La Mesa, California 91942 from BST on a month to month basis for $5,000 per month beginning January 14, 2022. BST Partners is controlled by David Koos who serves as the sole officer and director of Regen Biopharma, Inc.

ACCOUNTS RECEIVABLE, RELATED PA

ACCOUNTS RECEIVABLE, RELATED PARTY	9 Months Ended
	Jun. 30, 2022
Credit Loss [Abstract]
ACCOUNTS RECEIVABLE, RELATED PARTY	NOTE 7. ACCOUNTS RECEIVABLE, RELATED PARTY Accounts Receivable due from Related Party as of June 30, 2022 consists solely of amounts earned by the Company not yet paid resulting from the Company’s license agreement with KCL Therapeutics (See Note 6)

STOCKHOLDERS_ EQUITY

STOCKHOLDERS’ EQUITY	9 Months Ended
	Jun. 30, 2022
Equity [Abstract]
STOCKHOLDERS’ EQUITY	NOTE 8. STOCKHOLDERS’ EQUITY The stockholders’ equity section of the Company contains the following classes of capital stock as of June 30 2022: Common stock, $ 0 .0001 par value; 5,800,000,000 shares authorized: 4,920,002,832 shares issued and outstanding. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Common Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Common Stock owned by such holder times one (1). On any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Common Stock shall receive, out of assets legally available for distribution to the Company’s stockholders, a ratable share in the assets of the Corporation. Preferred Stock, $ 0.0001 par value, 800,000,000 shares authorized of which 600,000 is designated as Series AA Preferred Stock: 50,000 shares issued and outstanding as of June 30, 2022, 540,000,000 is designated Series A Preferred Stock of which 439,293,406 shares are outstanding as of June 30, 2022, 60,000,000 is designated Series M Preferred Stock of which 44,000,000 shares are outstanding as of June 30, 2022, and 20,000 is designated Series NC stock of which 10 ,000 shares are outstanding as of June 30, 2022. . The abovementioned shares authorized pursuant to the Company’s certificate of incorporation may be issued from time to time without prior approval of the shareholders. The Board of Directors of the Company shall have the full authority permitted by law to establish one or more series and the number of shares constituting each such series and to fix by resolution full or limited, multiple or fractional, or no voting rights, and such designations, preferences, qualifications, restrictions, options, conversion rights and other special or relative rights of any series of the Stock that may be desired. On September 15, 2014 the Company filed a CERTIFICATE OF DESIGNATION (“Certificate of Designations”) with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as “Series AA Preferred Stock” (hereinafter referred to as “Series AA Preferred Stock”). The Board of Directors of the Company have authorized 600,000 shares of the Series AA Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series AA Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series AA Preferred Stock owned by such holder times ten thousand (10,000). Except as otherwise required by law holders of Common Stock, other series of Preferred issued by the Corporation, and Series AA Preferred Stock shall vote as a single class on all matters submitted to the stockholders. Series A Preferred Stock On January 15, 2015 the Company filed a CERTIFICATE OF DESIGNATION (“Certificate of Designations”) with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as “Series A Preferred Stock” (hereinafter referred to as “Series A Preferred Stock”). The Board of Directors of the Company have authorized 540,000,000 shares of the Series A Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series A Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series A Preferred Stock owned by such holder times one . Except as otherwise required by law holders of Common Stock, other series of Preferred issued by the Corporation, and Series A Preferred Stock shall vote as a single class on all matters submitted to the stockholders. Holders of the Series A Preferred Stock will be entitled to receive, when, as and if declared by the board of directors of the Company (the “Board”) out of funds legally available therefore, non-cumulative cash dividends of $0.01 per quarter. In the event any dividends are declared or paid or any other distribution is made on or with respect to the Common Stock , the holders of Series A Preferred Stock as of the record date established by the Board for such dividend or distribution on the Common Stock shall be entitled to receive, as additional dividends (the “Additional Dividends”) an amount (whether in the form of cash, securities or other property) equal to the amount (and in the form) of the dividends or distribution that such holder would have received had each share of the Series A Preferred Stock been one share of the Common Stock, such Additional Dividends to be payable on the same payment date as the payment date for the Common Stock. Upon any liquidation, dissolution, or winding up of the Company, whether voluntary or involuntary (collectively, a “Liquidation”), before any distribution or payment shall be made to any of the holders of Common Stock or any other series of preferred stock, the holders of Series A Preferred Stock shall be entitled to receive out of the assets of the Company, whether such assets are capital, surplus or earnings, an amount equal to $0.01 per share of Series A Preferred (the “Liquidation Amount”) plus all declared and unpaid dividends thereon, for each share of Series A Preferred held by them. If, upon any Liquidation, the assets of the Company shall be insufficient to pay the Liquidation Amount, together with declared and unpaid dividends thereon, in full to all holders of Series A Preferred, then the entire net assets of the Company shall be distributed among the holders of the Series A Preferred, ratably in proportion to the full amounts to which they would otherwise be respectively entitled and such distributions may be made in cash or in property taken at its fair value (as determined in good faith by the Board), or both, at the election of the Board. On January 10, 2017 Regen Biopharma, Inc. (“Regen”) filed a CERTIFICATE OF DESIGNATION ("Certificate of Designations") with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as "Series M Preferred Stock" (hereinafter referred to as "Series M Preferred Stock"). The holders of Series M Preferred Stock shall be entitled receive dividends, when, as and if declared by the Board of Directors in accordance with Nevada Law, in its discretion, from funds legally available therefore On any voluntary or involuntary liquidation, dissolution or winding up of Regen, the holders of the Series M Preferred Stock shall receive, out of assets legally available for distribution to Regen’s stockholders, a ratable share in the assets of Regen. On March 26, 2021 Regen Biopharma, Inc. ( “Regen”) filed a CERTIFICATE OF DESIGNATION ("Certificate of Designations") with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as Nonconvertible Series NC Preferred Stock (hereinafter referred to as "Series NC Preferred Stock"). The Board of Directors of Regen have authorized 20,000 shares of the Series NC Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of Regen, each holder of Series NC Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series NC Preferred Stock owned by such holder times 500,000. Except as otherwise required by law holders of Common Stock, other series of Preferred issued by Regen, and Series NC Preferred Stock shall vote as a single class on all matters submitted to the stockholders. The holders of Series NC Preferred Stock shall be entitled receive dividends, when, as and if declared by the Board of Directors in accordance with Nevada Law, in its discretion, from funds legally available therefore On any voluntary or involuntary liquidation, dissolution or winding up of Regen, the holders of the Series NC Preferred Stock shall receive, out of assets legally available for distribution to Regen’s stockholders, a ratable share in the assets of Regen.

INVESTMENT SECURITIES, RELATED

INVESTMENT SECURITIES, RELATED PARY	9 Months Ended
	Jun. 30, 2022
Investment Securities Related Pary
INVESTMENT SECURITIES, RELATED PARY	NOTE 9. INVESTMENT SECURITIES, RELATED PARY On June 11, 2018 Regen Biopharma, Inc. was paid a property dividend consisting of 470,588 of the common shares of Zander Therapeutics, Inc. On November 29, 2018 the Company accepted 725,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. in satisfaction of prepaid rent and accrued interest owed to the Company collectively amounting to $ 13,124 . On June 30,2022 the Company revalued 470,588 of the common shares of Zander Therapeutics, Inc. and 725,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. based on the following inputs: Schedule of dividend income Fair Value of Intellectual Property $ 1,500 Prepaid Expenses 65,661 Due from Employee 1,071 Note Receivable 64,400 Accrued Interest Receivable 23,989 Investment Securities 8,423,366 Convertible Note Receivable 10,000 Accounts Payable 1,269,041 Notes Payable 400,000 Accrued Expenses Related Parties 162,011 Notes Payable Related Party 5396 Accrued Expenses 203,037 Enterprise Value 10,563,930 Less: Total Debt ( 2,038,343 ) Portion of Enterprise Value Attributable to Shareholders 8,525,587 Fair Value Per Share $ 0.186168 The abovementioned constitute the Company’s sole related party investment securities as of June 30, 2022 As of June 30, 2022: 470,588 Common Shares of Zander Therapeutics, Inc. Schedule of comprehensive income Basis Fair Value Total Unrealized Net Unrealized Gain or (Loss) realized during the quarter ended June 30,2022 $ 5,741 $ 87,608 $ 81,867 $ 79,749 725,000 Series M Preferred of Zander Therapeutics, Inc. Basis Fair Value Total Unrealized Gain Net Unrealized Gain or (Loss) realized during the quarter ended June 30, 2022 $ $13,124 $ 134,971 $ 121,847 $ 122,861

INVESTMENT SECURITIES

INVESTMENT SECURITIES	9 Months Ended
	Jun. 30, 2022
Disclosure Investment Securities Abstract
INVESTMENT SECURITIES	NOTE 10. INVESTMENT SECURITIES During the quarter ended June 30, 2021 the Company was paid 50,000 common shares of Oncology Pharma, Inc. pursuant to an agreement entered into by and between KCL Therapeutics, Inc. ( a wholly owned subsidiary of the Company) and Oncology Pharma, Inc. whereby Oncology Pharma, Inc. was granted a license for the development and commercialization of certain intellectual property (“License IP”) for the treatment in humans of colon cancer for a term of fifteen years from April 7, 2021. During the quarter ended June 30, 2021 13,000 of the aforementioned common shares were sold to an unrelated party for $ 300,000 cash. During the quarter ended September 30, 2021 18,000 of the aforementioned common shares were sold to an unrelated party for $ 195,000 cash. As of June 30, 2022 18,300 common shares of Oncology Pharma, Inc. constitute the sole investment securities other than shares of Zander Therapeutics, Inc. held by the Company. On June 30,2022 the Company revalued 18,300 common shares of Oncology Pharma, Inc. at the closing price of the common shares on the OTC Pink market. As of June 30, 2022: 18,300 Common Shares of Oncology Pharma, Inc. Schedule of investment securities Basis Fair Value Total Unrealized Net Unrealized Gain or (Loss) realized during the quarter ended June 30,2022 $ 677,100 $ 26,828 $ (650,272 ) $

STOCK TRANSACTIONS

STOCK TRANSACTIONS	9 Months Ended
	Jun. 30, 2022
Stock Transactions
STOCK TRANSACTIONS	NOTE 12. STOCK TRANSACTIONS On April 5, 2022 the Company issued 40,000,000 common shares in satisfaction of $ 218,617 of convertible indebtedness and $ 1,701 of accrued interest on convertible indebtedness. On April 8, 2022 the Company issued 100,000,000 common shares in satisfaction of $ 550,161 of convertible indebtedness and $ 1,500 of accrued interest on convertible indebtedness. On May 16, 2022 the Company issued 100,000,000 common shares in satisfaction of $ 334,800 of convertible indebtedness. On June 9, 2022 the Company issued 100,000,000 common shares in satisfaction of $ 334,800 of convertible indebtedness.

RESTATEMENT OF PREVIOUSLY ISSUD

RESTATEMENT OF PREVIOUSLY ISSUD FINANCIAL STATEMENTS	9 Months Ended
	Jun. 30, 2022
Restatement Of Previously Issud Financial Statements
RESTATEMENT OF PREVIOUSLY ISSUD FINANCIAL STATEMENTS	NOTE 13. RESTATEMENT OF PREVIOUSLY ISSUD FINANCIAL STATEMENTS Subsequent to the original issuance of Regen’s quarterly financial statements for the period ended June 30, 2021 the Company determined that the following revisions are required Recognizing revenue of $ 1,905,000 resulting from licensing fees paid during the quarter ended June 30,2021 over the term of the license ( 15 years) Cumulative Effect of Restatement of Previously Issued Financial Statements for the Quarter Ended June 30, 2021. Schedule of restatement of previously issued financial statements Statement of Operations As Originally Presented Adjustments As Restated Three Months Ended June 30,2021 Revenues 1,905,000 (1,875,794 ) 29,206 Total Revenues 1,932,425 (1,875,794 ) 56,631 Net Income ( Loss) (5,613,321 ) (1,875,794 ) (7,489,115 ) Nine Months Ended June 30,2021 Revenues 1,905,000 (1,875,794 ) 29,206 Total Revenues 1,987,274 (1,875,794 ) 111,480 Net Income ( Loss) (3,504,772 ) (1,875,794 ) (5,380,566 ) Statement of Cash Flow As Originally Presented Adjustments As Restated for the Nine Months Ended June 30,2021 Increase in Unearned Income 0 1,875,794 1,875,794 Statement of Shareholders' Equity ( Deficit) As Originally Presented Adjustments As Restated for the Nine Months Ended June 30,2021 Net Loss for the Quarter Ended June 30,2021 (5,613,321 ) (1,875,794 ) (7,489,115 ) Balance Sheet as of June 30,2021 As Originally Presented Adjustments As Restated Unearned Income 0 1,875,794 1,875,794 Current Liabilities 11,969,547 1,875,794 13,845,341 Total Liabilities 11,969,547 1,875,794 13,845,341 Retained Earnings (Deficit) (20,088,438 ) (1,875,794 ) (21,964,232 ) Total Stockholders' Equity (Deficit) (10,535,891 ) (1,875,794 ) (12,411,685 )

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Jun. 30, 2022
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 14. SUBSEQUENT EVENTS On July 15 2022 the Company issued 50,000,000 common shares in satisfaction of $ 132,650 of convertible indebtedness and $ 32,950 of accrued interest on convertible indebtedness. On July 19, 2022 the Company issued 54,514,492 180,552

ORGANIZATION AND SUMMARY OF S_2

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
BASIS OF ACCOUNTING	A. BASIS OF ACCOUNTING The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a September 30 year-end.
PRINCIPLES OF CONSOLIDATION	B. PRINCIPLES OF CONSOLIDATION The consolidated financial statements include the accounts of KCL Therapeutics, Inc., a Nevada corporation and wholly owned subsidiary of Regen. Significant inter-company transactions have been eliminated. The Company analyzes the conversion feature of Convertible Notes for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model. The Black Scholes pricing model used to determine the Derivative Liability on convertible notes issued by the Company in which an embedded derivative is recognized as of June 30, 2022 utilized the following inputs: Schedule of Derivative Liability Risk Free Interest Rate 2.98 % Expected Term .( 0.5 ) – ( 2.88 ) Yrs Expected Volatility 855.05 % Expected Dividends
INCOME TAXES	H. INCOME TAXES The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date. The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of September 30, 2021 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future. The Company generated a deferred tax credit through net operating loss carry forward. However, a valuation allowance of 100 % has been established. Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.
BASIC EARNINGS (LOSS) PER SHARE	I. BASIC EARNINGS (LOSS) PER SHARE The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, “Earnings Per Share”, which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception. Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding.
ADVERTISING	ADVERTISING Costs associated with advertising are charged to expense as incurred. Advertising expenses were $ 0 for the quarters ended June 30,2021 and June 30, 2022.
NOTES RECEIVABLE	K. NOTES RECEIVABLE Notes receivable are stated at cost, less impairment, if any. As of June 30,2022 the Company has the following Notes Receivable Schedule of notes receivable Zander Therapeutics, Inc. $ 5,396 $5,396 owed to the Company by Zander Therapeutics, Inc. bears simple interest at 10% and is due upon the demand of the Company.
REVENUE RECOGNITION	L. REVENUE RECOGNITION Sales of products and related costs of products sold are recognized when: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred; (iii) the price is fixed or determinable; and (iv) collectability is reasonably assured. These terms are typically met upon the prepayment or invoicing and shipment of products. The Company determines the amount and timing of royalty revenue based on its contractual agreements with intellectual property licensees. The Company recognizes royalty revenue when earned under the terms of the agreements and when the Company considers realization of payment to be probable. Where royalties are based on a percentage of licensee sales of royalty-bearing products, the Company recognizes royalty revenue by applying this percentage to the Company’s estimate of applicable licensee sales. The Company bases this estimate on an analysis of each licensee’s sales results. Where warranted, revenue from licensees for contractual obligations such as License Initiation Fees are recognized upon satisfaction of all conditions required to be satisfied in order for that revenue to have been earned by the Company.
INTEREST RECEIVABLE	M. INTEREST RECEIVABLE Interest receivable is stated at cost, less impairment, if any.

ORGANIZATION AND SUMMARY OF S_3

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Schedule of Derivative Liability	Schedule of Derivative Liability Risk Free Interest Rate 2.98 % Expected Term .( 0.5 ) – ( 2.88 ) Yrs Expected Volatility 855.05 % Expected Dividends
Schedule of notes receivable	Schedule of notes receivable Zander Therapeutics, Inc. $ 5,396

NOTES PAYABLE (Tables)

NOTES PAYABLE (Tables)	9 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Schedule of notes payable related party	Schedule of notes payable related party As of June 30, 2022 David Koos $ 227 Total: $ 227

INVESTMENT SECURITIES, RELATE_2

INVESTMENT SECURITIES, RELATED PARY (Tables)	9 Months Ended
	Jun. 30, 2022
Investment Securities Related Pary
Schedule of dividend income	Schedule of dividend income Fair Value of Intellectual Property $ 1,500 Prepaid Expenses 65,661 Due from Employee 1,071 Note Receivable 64,400 Accrued Interest Receivable 23,989 Investment Securities 8,423,366 Convertible Note Receivable 10,000 Accounts Payable 1,269,041 Notes Payable 400,000 Accrued Expenses Related Parties 162,011 Notes Payable Related Party 5396 Accrued Expenses 203,037 Enterprise Value 10,563,930 Less: Total Debt ( 2,038,343 ) Portion of Enterprise Value Attributable to Shareholders 8,525,587 Fair Value Per Share $ 0.186168
Schedule of comprehensive income	Schedule of comprehensive income Basis Fair Value Total Unrealized Net Unrealized Gain or (Loss) realized during the quarter ended June 30,2022 $ 5,741 $ 87,608 $ 81,867 $ 79,749 725,000 Series M Preferred of Zander Therapeutics, Inc. Basis Fair Value Total Unrealized Gain Net Unrealized Gain or (Loss) realized during the quarter ended June 30, 2022 $ $13,124 $ 134,971 $ 121,847 $ 122,861

INVESTMENT SECURITIES (Tables)

INVESTMENT SECURITIES (Tables)	9 Months Ended
	Jun. 30, 2022
Disclosure Investment Securities Abstract
Schedule of investment securities	Schedule of investment securities Basis Fair Value Total Unrealized Net Unrealized Gain or (Loss) realized during the quarter ended June 30,2022 $ 677,100 $ 26,828 $ (650,272 ) $

RESTATEMENT OF PREVIOUSLY ISS_2

RESTATEMENT OF PREVIOUSLY ISSUD FINANCIAL STATEMENTS (Tables)	9 Months Ended
	Jun. 30, 2022
Restatement Of Previously Issud Financial Statements
Schedule of restatement of previously issued financial statements	Schedule of restatement of previously issued financial statements Statement of Operations As Originally Presented Adjustments As Restated Three Months Ended June 30,2021 Revenues 1,905,000 (1,875,794 ) 29,206 Total Revenues 1,932,425 (1,875,794 ) 56,631 Net Income ( Loss) (5,613,321 ) (1,875,794 ) (7,489,115 ) Nine Months Ended June 30,2021 Revenues 1,905,000 (1,875,794 ) 29,206 Total Revenues 1,987,274 (1,875,794 ) 111,480 Net Income ( Loss) (3,504,772 ) (1,875,794 ) (5,380,566 ) Statement of Cash Flow As Originally Presented Adjustments As Restated for the Nine Months Ended June 30,2021 Increase in Unearned Income 0 1,875,794 1,875,794 Statement of Shareholders' Equity ( Deficit) As Originally Presented Adjustments As Restated for the Nine Months Ended June 30,2021 Net Loss for the Quarter Ended June 30,2021 (5,613,321 ) (1,875,794 ) (7,489,115 ) Balance Sheet as of June 30,2021 As Originally Presented Adjustments As Restated Unearned Income 0 1,875,794 1,875,794 Current Liabilities 11,969,547 1,875,794 13,845,341 Total Liabilities 11,969,547 1,875,794 13,845,341 Retained Earnings (Deficit) (20,088,438 ) (1,875,794 ) (21,964,232 ) Total Stockholders' Equity (Deficit) (10,535,891 ) (1,875,794 ) (12,411,685 )

ORGANIZATION AND SUMMARY OF S_4

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)	9 Months Ended
	Jun. 30, 2022
Property, Plant and Equipment [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	2.98%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate	855.05%
Minimum [Member]
Property, Plant and Equipment [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term	6 months
Maximum [Member]
Property, Plant and Equipment [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term	2 years 10 months 17 days

ORGANIZATION AND SUMMARY OF S_5

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)	Jun. 30, 2022 USD ($)
Zander Therapeutics [Member]
Defined Benefit Plan Disclosure [Line Items]
Long-term Investments and Receivables, Net	$ 5,396

ORGANIZATION AND SUMMARY OF S_6

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	9 Months Ended	15 Months Ended
	Jun. 30, 2022	Jun. 30, 2022
Accounting Policies [Abstract]
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent	100%
Advertising Expense		$ 0

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative)	122 Months Ended
	Jun. 30, 2022 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
[custom:NetIncomeLossSinceInception]	$ 20,827,342

NOTES PAYABLE (Details)

NOTES PAYABLE (Details)	Jun. 30, 2022 USD ($)
Short-Term Debt [Line Items]
Notes Payable	$ 227
David Koos [Member]
Short-Term Debt [Line Items]
Notes Payable	$ 227

NOTES PAYABLE (Details Narrativ

NOTES PAYABLE (Details Narrative) - David Koos [Member]	9 Months Ended
	Jun. 30, 2022 USD ($)
Long-Term Debt, Gross	$ 227
Debt Instrument, Interest Rate During Period	15%

CONVERTIBLE NOTES PAYABLE (Deta

CONVERTIBLE NOTES PAYABLE (Details Narrative) - USD ($)	3 Months Ended	9 Months Ended
	Jun. 30, 2022	Jun. 30, 2022	Jun. 20, 2022	Jun. 30, 2021
Short-Term Debt [Line Items]
Payments for Other Fees	$ 1,905,000
Other Expenses		$ 300,000
Convertible Note; March 8, 2016
Short-Term Debt [Line Items]
Convertible Notes Payable, Current	100,000	100,000
[custom:CashIssuedForConvertibleNote-0]	$ 100,000	$ 100,000
Debt Instrument, Interest Rate, Effective Percentage	8%	8%
Notes Payable, Current	$ 100,000	$ 100,000
Convertible Note; April 6, 2016
Short-Term Debt [Line Items]
Convertible Notes Payable, Current	50,000	50,000
[custom:CashIssuedForConvertibleNote-0]	$ 50,000	$ 50,000
Debt Instrument, Interest Rate, Effective Percentage	8%	8%
Notes Payable, Current			$ 50,000
Convertible Note; October 31, 2016
Short-Term Debt [Line Items]
Convertible Notes Payable, Current	$ 50,000	$ 50,000
[custom:CashIssuedForConvertibleNote-0]	$ 50,000	$ 50,000
Debt Instrument, Interest Rate, Effective Percentage	10%	10%
Notes Payable, Current	$ 50,000	$ 50,000
Debt Instrument, Convertible, Conversion Price	$ 0.0125	$ 0.0125
Convertible Note 1; October 31, 2016
Short-Term Debt [Line Items]
Convertible Notes Payable, Current	$ 50,000	$ 50,000
[custom:CashIssuedForConvertibleNote-0]	$ 50,000	$ 50,000
Debt Instrument, Interest Rate, Effective Percentage	10%	10%
Notes Payable, Current	$ 50,000	$ 50,000
Convertible Note 2; October 31, 2016
Short-Term Debt [Line Items]
Convertible Notes Payable, Current	50,000	50,000
[custom:CashIssuedForConvertibleNote-0]	$ 50,000	$ 50,000
Debt Instrument, Interest Rate, Effective Percentage	10%	10%
Notes Payable, Current				$ 50,000
Convertible Note; March 13, 2017
Short-Term Debt [Line Items]
Convertible Notes Payable, Current	$ 50,000	$ 50,000
[custom:CashIssuedForConvertibleNote-0]	$ 50,000	$ 50,000
Debt Instrument, Interest Rate, Effective Percentage	10%	10%
Debt Instrument, Convertible, If-converted Value in Excess of Principal		$ 50,000
Convertible Note: March 31, 2017
Short-Term Debt [Line Items]
Derivative Liability, Current	$ 177,778	177,778
March 3120171 [Member]
Short-Term Debt [Line Items]
Convertible Notes Payable, Current	50,000	50,000
[custom:CashIssuedForConvertibleNote-0]	$ 50,000	$ 50,000
Debt Instrument, Interest Rate, Effective Percentage	10%	10%
Debt Instrument, Convertible, If-converted Value in Excess of Principal		$ 50,000
Derivative Liability, Current	$ 177,778	177,778
Convertible Note; April 19, 2017
Short-Term Debt [Line Items]
Convertible Notes Payable, Current	50,000	50,000
[custom:CashIssuedForConvertibleNote-0]	$ 50,000	$ 50,000
Debt Instrument, Interest Rate, Effective Percentage	10%	10%
Notes Payable, Current	$ 50,000	$ 50,000
Derivative Liability, Current	177,778	177,778
Convertible Note; May 5, 2017
Short-Term Debt [Line Items]
Convertible Notes Payable, Current	200,000	200,000
[custom:CashIssuedForConvertibleNote-0]	$ 200,000	$ 200,000
Debt Instrument, Interest Rate, Effective Percentage	10%	10%
Debt Instrument, Convertible, If-converted Value in Excess of Principal		$ 200,000
Derivative Liability, Current	$ 711,111	711,111
Convertible Note; June 26, 2017
Short-Term Debt [Line Items]
Convertible Notes Payable, Current	150,000	150,000
[custom:CashIssuedForConvertibleNote-0]	$ 150,000	$ 150,000
Debt Instrument, Interest Rate, Effective Percentage	10%	10%
Debt Instrument, Convertible, If-converted Value in Excess of Principal		$ 150,000
Derivative Liability, Current	$ 533,333	533,333
Convertible Note; September 25, 2017
Short-Term Debt [Line Items]
Convertible Notes Payable, Current	50,000	50,000
[custom:CashIssuedForConvertibleNote-0]	$ 50,000	$ 50,000
Debt Instrument, Interest Rate, Effective Percentage	10%	10%
Debt Instrument, Convertible, If-converted Value in Excess of Principal		$ 50,000
Derivative Liability, Current	$ 177,778	177,778
Convertible Note; October 3, 2017
Short-Term Debt [Line Items]
Convertible Notes Payable, Current	50,000	50,000
[custom:CashIssuedForConvertibleNote-0]	$ 50,000	$ 50,000
Debt Instrument, Interest Rate, Effective Percentage	10%	10%
Debt Instrument, Convertible, If-converted Value in Excess of Principal		$ 50,000
Derivative Liability, Current	$ 177,778	177,778
Convertible Note; October 16, 2017
Short-Term Debt [Line Items]
Convertible Notes Payable, Current	100,000	100,000
[custom:CashIssuedForConvertibleNote-0]	$ 100,000	$ 100,000
Debt Instrument, Interest Rate, Effective Percentage	10%	10%
Debt Instrument, Convertible, If-converted Value in Excess of Principal		$ 100,000
Derivative Liability, Current	$ 355,556	355,556
Convertible Note; November 01, 2017
Short-Term Debt [Line Items]
Convertible Notes Payable, Current	25,000	25,000
[custom:CashIssuedForConvertibleNote-0]	$ 25,000	$ 25,000
Debt Instrument, Interest Rate, Effective Percentage	10%	10%
Debt Instrument, Convertible, If-converted Value in Excess of Principal		$ 25,000
Derivative Liability, Current	$ 88,889	88,889
Convertible Note; 2 November 1, 2017
Short-Term Debt [Line Items]
Convertible Notes Payable, Current	25,000	25,000
[custom:CashIssuedForConvertibleNote-0]	$ 25,000	$ 25,000
Debt Instrument, Interest Rate, Effective Percentage	10%	10%
Debt Instrument, Convertible, If-converted Value in Excess of Principal		$ 25,000
Derivative Liability, Current	$ 88,889	88,889
Convertible Note; December 20, 2017
Short-Term Debt [Line Items]
Convertible Notes Payable, Current	100,000	100,000
[custom:CashIssuedForConvertibleNote-0]	$ 100,000	$ 100,000
Debt Instrument, Interest Rate, Effective Percentage	10%	10%
Debt Instrument, Convertible, If-converted Value in Excess of Principal		$ 100,000
Derivative Liability, Current	$ 355,556	355,556
Convertible Note; February 28, 2018
Short-Term Debt [Line Items]
Convertible Notes Payable, Current	100,000	100,000
[custom:CashIssuedForConvertibleNote-0]	$ 100,000	$ 100,000
Debt Instrument, Interest Rate, Effective Percentage	10%	10%
Debt Instrument, Convertible, If-converted Value in Excess of Principal		$ 100,000
Derivative Liability, Current	$ 355,556	355,556
Convertible Note; July 11, 2018
Short-Term Debt [Line Items]
Convertible Notes Payable, Current	11,500	11,500
[custom:CashIssuedForConvertibleNote-0]	$ 11,500	$ 11,500
Debt Instrument, Interest Rate, Effective Percentage	10%	10%
Debt Instrument, Convertible, If-converted Value in Excess of Principal		$ 11,500
Derivative Liability, Current	$ 40,889	40,889
Convertible Note; September 30, 2018
Short-Term Debt [Line Items]
Convertible Notes Payable, Current	350,000	350,000
[custom:CashIssuedForConvertibleNote-0]	$ 350,000	$ 350,000
Debt Instrument, Interest Rate, Effective Percentage	10%	10%
Notes Payable, Current	$ 10,000	$ 10,000
Debt Instrument, Convertible, If-converted Value in Excess of Principal		10,000
Convertible Note; July 19, 2019
Short-Term Debt [Line Items]
Convertible Notes Payable, Current	100,000	100,000
[custom:CashIssuedForConvertibleNote-0]	95,000	95,000
Notes Payable, Current	1,000	1,000
Derivative Liability, Current	1,093	1,093
Convertible Note ; September 17, 2021
Short-Term Debt [Line Items]
Convertible Notes Payable, Current	1,500,000	1,500,000
[custom:CashIssuedForConvertibleNote-0]	$ 75,000	$ 75,000
Debt Instrument, Interest Rate, Effective Percentage	5%	5%
Payments for Other Fees		$ 1,390,000
Debt Instrument, Periodic Payment		312,500
Convertible Note ; March 17, 2022
Short-Term Debt [Line Items]
Notes Payable, Current	$ 313,201	313,201
Derivative Liability, Current	$ 234,243	$ 234,243

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative)	Jun. 30, 2022 USD ($)
Short-Term Debt [Line Items]
Notes Payable, Related Parties, Current	$ 227
Convertible Note; September 30, 2018
Short-Term Debt [Line Items]
Convertible Notes Payable, Current	350,000
Notes Payable, Current	10,000
David Koos [Member]
Short-Term Debt [Line Items]
Notes Payable, Related Parties, Current	227
Long-Term Debt, Gross	$ 227

STOCKHOLDERS_ EQUITY (Details N

STOCKHOLDERS’ EQUITY (Details Narrative) - $ / shares	Jun. 30, 2022	Sep. 30, 2021
Class of Stock [Line Items]
Common Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Common Stock, Shares Authorized	5,800,000,000	4,800,000,000
Common Stock, Shares, Outstanding	4,920,002,832	4,350,554,514
Preferred Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Preferred Stock, Shares Authorized	800,000,000	800,000,000
Series A A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Par or Stated Value Per Share		$ 0.0001
Preferred Stock, Shares Authorized	600,000	600,000
Preferred Stock, Shares Outstanding	50,000	50,000
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Authorized	540,000,000	300,000,000
Preferred Stock, Shares Outstanding	439,293,406	431,998,817
Series M [Member]
Class of Stock [Line Items]
Preferred Stock, Par or Stated Value Per Share		$ 0.0001
Preferred Stock, Shares Authorized	60,000,000	300,000,000
Preferred Stock, Shares Outstanding	44,000,000	44,000,000
Series N C [Member]
Class of Stock [Line Items]
Preferred Stock, Par or Stated Value Per Share		$ 0.0001
Preferred Stock, Shares Authorized	20,000	20,000
Preferred Stock, Shares Outstanding	10	10

INVESTMENT SECURITIES, RELATE_3

INVESTMENT SECURITIES, RELATED PARY (Details) - USD ($)	Jun. 30, 2022	Sep. 30, 2021
Prepaid Expense, Current	$ 27,801	$ 48,144
Accrued Investment Income Receivable	629	230
Accounts Payable, Current	28,799	$ 91,498
Notes Payable, Related Parties, Current	227
Common Stock [Member] | Zander Therapeutics [Member]
[custom:FairValueOfIntellectualProperty-0]	1,500
Prepaid Expense, Current	65,661
Due from Employees	1,071
Receivables, Net, Current	64,400
Accrued Investment Income Receivable	23,989
Investments	8,423,366
[custom:ConvertibleNoteReceivable-0]	10,000
Accounts Payable, Current	1,269,041
Notes Payable	400,000
[custom:AccruedExpensesRelated-0]	162,011
Notes Payable, Related Parties, Current	5,396
Accrued Liabilities, Current	203,037
[custom:EnterpriseValue-0]	10,563,930
Debt, Current	2,038,343
[custom:PortionOfEnterpriseValueAttributableToShareholders-0]	$ 8,525,587
[custom:FairValuePerShare-0]	$ 0.186168

INVESTMENT SECURITIES, RELATE_4

INVESTMENT SECURITIES, RELATED PARY (Details 1) - USD ($)	9 Months Ended
	Jun. 30, 2022	Sep. 30, 2021
Investment Securities, Fair Value	$ 26,828	$ 198,006
Common Stock [Member] | Zander Therapeutics [Member]
Investment Securities, Basis	5,741
Investment Securities, Fair Value	87,608
Investment Securities, Total Unrealized Gain	81,867
Investment Securities, net Unrealized Gain or (Loss) realized	79,749
Series M [Member] | Zander Therapeutics [Member]
Investment Securities, Basis	13,124
Investment Securities, Fair Value	134,971
Investment Securities, Total Unrealized Gain	121,847
Investment Securities, net Unrealized Gain or (Loss) realized	$ 122,861

INVESTMENT SECURITIES, RELATE_5

INVESTMENT SECURITIES, RELATED PARY (Details Narrative) - Zander Therapeutics [Member] - USD ($)		1 Months Ended	9 Months Ended
	Jun. 11, 2019	Nov. 29, 2019	Jun. 30, 2022
[custom:NumberOfSharesIssuedForPropertyDividend]	470,588		470,588
Series M [Member]
[custom:NumberOfSharesIssuedInSatisfactionOfPrepaidRentAndAccruedInterest]		725,000	725,000
[custom:SharesIssuedInSatisfactionOfPrepaidRentAndAccruedInterestValue]		$ 13,124

INVESTMENT SECURITIES (Details)

INVESTMENT SECURITIES (Details) - USD ($)	Jun. 30, 2022	Sep. 30, 2021
Available-for-sale Securities	$ 26,828	$ 198,006
Common Stock [Member] | Oncology Pharma [Member]
Investment Securities, Basis	677,100
Available-for-sale Securities	26,828
Investment Securities, Total Unrealized Gain	$ (650,272)

INVESTMENT SECURITIES (Details

INVESTMENT SECURITIES (Details Narrative) - USD ($)	3 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Jun. 30, 2022
Common Stock [Member]
Shares, Issued			18,300
Common Stock [Member] | Zander Therapeutics [Member]
Shares, Issued			18,300
Unrelated Party [Member]
Sale of Stock, Number of Shares Issued in Transaction	18,000	13,000
Proceeds from Issuance or Sale of Equity	$ 195,000	$ 300,000

STOCK TRANSACTIONS (Details Nar

STOCK TRANSACTIONS (Details Narrative) - Convertible Debt [Member] - Common Stock [Member] - USD ($)				1 Months Ended
	Jun. 09, 2022	Apr. 08, 2022	Apr. 05, 2022	May 16, 2022
Short-Term Debt [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities	100,000,000	100,000,000	40,000,000	100,000,000
[custom:StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities]	$ 334,800	$ 550,161	$ 218,617	$ 334,800
Interest Expense, Debt		$ 1,500	$ 1,701

RESTATEMENT OF PREVIOUSLY ISS_3

RESTATEMENT OF PREVIOUSLY ISSUD FINANCIAL STATEMENTS (Details) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020
Revenues	$ 31,292	$ 29,206	$ 93,877	$ 29,206
Total Revenues	58,717	56,631	176,151	111,480
Net Loss	66,958,166	(7,489,114)	2,521,557	(5,380,566)
Increase in Unearned Income			(93,877)	1,875,794
Unearned Income	1,749,930		1,749,930				$ 1,843,806
Current Liabilities	9,039,377		9,039,377				14,697,976
Total Liabilities	9,039,377		9,039,377				14,697,976
Retained Earnings (Deficit)	(20,827,342)		(20,827,342)				(23,348,900)
Total Stockholders' Equity (Deficit)	$ (8,349,684)	(12,411,685)	$ (8,349,684)	(12,411,685)	$ (76,749,430)	$ (9,755,969)	$ (13,485,877)	$ (5,070,713)	$ (5,581,256)	$ (7,334,998)
As Originally Presented [Member]
Revenues		1,905,000		1,905,000
Total Revenues		1,932,425		1,987,274
Net Loss		(5,613,321)		(3,504,772)
Increase in Unearned Income				0
Unearned Income		0		0
Current Liabilities		11,969,547		11,969,547
Total Liabilities		11,969,547		11,969,547
Retained Earnings (Deficit)		(20,088,438)		(20,088,438)
Total Stockholders' Equity (Deficit)		(10,535,891)		(10,535,891)
Revision of Prior Period, Adjustment [Member]
Revenues		(1,875,794)		(1,875,794)
Total Revenues		(1,875,794)		(1,875,794)
Net Loss		(1,875,794)		(1,875,794)
Increase in Unearned Income				1,875,794
Unearned Income		1,875,794		1,875,794
Current Liabilities		1,875,794		1,875,794
Total Liabilities		1,875,794		1,875,794
Retained Earnings (Deficit)		(1,875,794)		(1,875,794)
Total Stockholders' Equity (Deficit)		(1,875,794)		(1,875,794)
As Restated [Member]
Revenues		29,206		29,206
Total Revenues		56,631		111,480
Net Loss		(7,489,115)		(5,380,566)
Increase in Unearned Income				1,875,794
Unearned Income		1,875,794		1,875,794
Current Liabilities		13,845,341		13,845,341
Total Liabilities		13,845,341		13,845,341
Retained Earnings (Deficit)		(21,964,232)		(21,964,232)
Total Stockholders' Equity (Deficit)		$ (12,411,685)		$ (12,411,685)

RESTATEMENT OF PREVIOUSLY ISS_4

RESTATEMENT OF PREVIOUSLY ISSUD FINANCIAL STATEMENTS (Details Narrative)	3 Months Ended
	Jun. 30, 2022 USD ($)
Restatement Of Previously Issud Financial Statements
Payments for Other Fees	$ 1,905,000
[custom:LicenseTerm]	15 years

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - Convertible Debt [Member] - Common Stock [Member] - USD ($)					1 Months Ended
	Jul. 15, 2022	Jun. 09, 2022	Apr. 08, 2022	Apr. 05, 2022	Jul. 19, 2022	May 16, 2022
Subsequent Event [Line Items]
Shares issued in satisfaction of convertible identedness		100,000,000	100,000,000	40,000,000		100,000,000
Interest Expense, Debt			$ 1,500	$ 1,701
Subsequent Event [Member]
Subsequent Event [Line Items]
Shares issued in satisfaction of convertible identedness	50,000,000				54,514,492
Shares issued in satisfaction of convertible identedness value	$ 132,650				$ 180,552
Interest Expense, Debt	$ 32,950